Other languages IN8bio, Inc.

Equities

INAB

US45674E1091

Delayed Nasdaq Other stock markets 11:05:39 2024-04-25 am EDT			5-day change	1st Jan Change
1.047 ^USD	-1.22%		-0.28%	-24.12%

Apr. 10	Top Premarket Gainers	MT
Apr. 10	North American Morning Briefing: Traders Await the CPI Report	DJ

Other languages

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

Top Premarket Gainers	Apr. 10
IN8bio, Inc. Announces New Preclinical Data for Gamma-Delta nsCAR-T Cell Therapy Platform at AACR 2024	Apr. 09
IN8bio, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 14
IN8bio, Inc. to Present New Preclinical Data on Novel Gamma-Delta CAR Platform Candidate at AACR Annual Meeting 2024	Mar. 05
IN8bio Announces Publication on Novel Gamma-Delta T Cell Therapy for Glioblastoma in Frontiers in Immunology	Feb. 14
Wall Street Set to Open Slightly Higher Tuesday; Annual Inflation Declines to 3.1%	Dec. 12
Top Premarket Gainers	Dec. 12
IN8bio, Inc. Announces Positive Clinical Update Demonstrating Continued Durable Complete Remission in 100% of Evaluable Patients in Phase 1 Trial of INB-100 in Leukemia	Dec. 11
IN8bio Prices $46.9 Million Private Placement; Shares Surge 19%	Dec. 11
IN8bio, Inc. Appoints Corinne Epperly to the Board of Directors	Dec. 07
IN8bio, Inc.?s INB-200 Demonstrates Extended Progression-Free Survival in Patients with Newly Diagnosed Glioblastoma	Nov. 20
IN8bio, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 09
IN8bio, Inc. Presents Biologic Correlative Data from the Inb-200 Phase 1 Trial in Newly Diagnosed Glioblastoma At the Society for Immunotherapy of Cancer's 38Th Annual Meeting	Nov. 06
IN8bio, Inc. Presents Positive Data Update from Induced Pluripotent Stem Cell Platform at the Society for Immunotherapy of Cancer 38th Annual Meeting	Nov. 03
IN8bio, Inc. to Present New Positive Data from Phase 1 Trial of INB-100 at 2023 American Society of Hematology Annual Meeting	Nov. 02
IN8bio Completes Dose Escalation in Phase 1 Trial of INB-100, a Potential First-in-Class Gamma-Delta T Cell Therapy for the Treatment of Leukemias, and Initiates Enrollment for the Phase 2 Trial of INB-400 in Newly Diagnosed Glioblastoma	23-10-12
IN8bio, Inc. Announces Presentations at the Society for Immunology of Cancer 38th Annual Meeting	23-09-29
IN8bio Granted Patents for DeltEx DRI Platform With Chimeric Antigen Receptor T-cell, Checkpoint Inhibitors	23-09-19
IN8bio, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-10
IN8bio, Inc. Announces Updated Data from the Ongoing Phase 1 Clinical Trial of Inb-200 in Patients with Newly Diagnosed Glioblastoma Multiforme	23-06-05

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

Other languages IN8bio, Inc.

Equities

INAB

US45674E1091

Other languages

Filters